General Information of DTT (ID: TTDCBX5)

DTT Name Vascular endothelial growth factor receptor 3 (FLT-4) DTT Info
Gene Name FLT4

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
2 Approved Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fruquintinib DMHOSCQ Colorectal cancer 2B91.Z Approved [1]
Tivozanib DMUKC5L Renal cell carcinoma 2C90 Approved [2]
------------------------------------------------------------------------------------
11 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
ABT-869 DMREDYP Solid tumour/cancer 2A00-2F9Z Phase 3 [3]
E-3810 DM42PFT Solid tumour/cancer 2A00-2F9Z Phase 3 [4]
PI-88 DMGZPX6 Hepatocellular carcinoma 2C12.02 Phase 3 [5]
Sulfatinib DMPOTM4 Neuroendocrine cancer 2B72.1 Phase 3 [6]
Taberminogene vadenovec DMW5PHL Vascular restinosis BE2Z Phase 3 [7]
MGCD516 DM752PU Solid tumour/cancer 2A00-2F9Z Phase 2/3 [8]
Famitinib DMSFWT7 Solid tumour/cancer 2A00-2F9Z Phase 2 [9]
VATALANIB DMY0UEQ Solid tumour/cancer 2A00-2F9Z Phase 2 [10]
MK-2461 DM21WBH Alzheimer disease 8A20 Phase 1/2 [11]
IMC-3C5 DMXI5ON Solid tumour/cancer 2A00-2F9Z Phase 1 [12]
JNJ-26483327 DMSQ3AZ Solid tumour/cancer 2A00-2F9Z Phase 1 [13]
------------------------------------------------------------------------------------
⏷ Show the Full List of 11 Clinical Trial Drug(s)
1 Patented Agent(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pyrimidine derivative 15 DMV2Y84 N. A. N. A. Patented [14]
------------------------------------------------------------------------------------
20 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
(2-Methoxy-phenyl)-(5-phenyl-oxazol-2-yl)-amine DMQWD75 Discovery agent N.A. Investigative [10]
(5-Phenyl-oxazol-2-yl)-m-tolyl-amine DM1R5SF Discovery agent N.A. Investigative [10]
2-(5-Phenyl-oxazol-2-ylamino)-benzonitrile DMX6QMT Discovery agent N.A. Investigative [10]
3,6-Di-pyridin-4-yl-pyrazolo[1,5-a]pyrimidine DMNV0EZ Discovery agent N.A. Investigative [15]
3-(5-Phenyl-oxazol-2-ylamino)-benzonitrile DMPBLM2 Discovery agent N.A. Investigative [10]
4-(5-Phenyl-oxazol-2-ylamino)-benzenesulfonamide DM3N9O5 Discovery agent N.A. Investigative [10]
4-Chloro-N-(2-chloro-benzoyl)-benzenesulfonamide DMVJ61A Discovery agent N.A. Investigative [16]
4-Chloro-N-(2-methyl-benzoyl)-benzenesulfonamide DM6SI78 Discovery agent N.A. Investigative [16]
4-Chloro-N-(3-chloro-benzoyl)-benzenesulfonamide DMI3OR9 Discovery agent N.A. Investigative [16]
4-Chloro-N-(4-chloro-benzoyl)-benzenesulfonamide DMTDX2S Discovery agent N.A. Investigative [16]
4-Chloro-N-(4-nitro-benzoyl)-benzenesulfonamide DMM0TL6 Discovery agent N.A. Investigative [16]
Anti-VEGFR 3 mab DMAJ6TC Discovery agent N.A. Investigative [8]
CB-676475 DMXON4L Discovery agent N.A. Investigative [17]
CEP-6331 DMNXBTD Discovery agent N.A. Investigative [18]
N-(2,4-Dichloro-benzoyl)-benzenesulfonamide DMHI4Y6 Discovery agent N.A. Investigative [16]
N-(3-Bromo-benzoyl)-4-chloro-benzenesulfonamide DMOQ08F Discovery agent N.A. Investigative [16]
Phenyl-(5-phenyl-oxazol-2-yl)-amine DMR2B4O Discovery agent N.A. Investigative [10]
PMID22765894C8h DMH5RFU Discovery agent N.A. Investigative [19]
SAR-131675 DMSYE4W Solid tumour/cancer 2A00-2F9Z Investigative [8]
[3-(5-Phenyl-oxazol-2-ylamino)-phenyl]-methanol DMD0LCU Discovery agent N.A. Investigative [10]
------------------------------------------------------------------------------------
⏷ Show the Full List of 20 Investigative Drug(s)
Molecule Interaction Atlas

References

1 Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635-45.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
3 Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther. 2006 Apr;5(4):995-1006.
4 E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405.
5 Company report (Medigen)
6 Clinical pipeline report, company report or official report of Hutchison Medi Pharma.
7 Advances in kinase targeting: current clinical use and clinical trials. Trends Pharmacol Sci. 2014 Nov;35(11):604-20.
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1814).
9 Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
10 Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9.
11 MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
12 Bevacizumab and breast cancer: what does the future hold . Future Oncol. 2012 April; 8(4): 403-414.
13 National Cancer Institute Drug Dictionary (drug id 596693).
14 VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
15 Synthesis and initial SAR studies of 3,6-disubstituted pyrazolo[1,5-a]pyrimidines: a new class of KDR kinase inhibitors. Bioorg Med Chem Lett. 2002 Oct 7;12(19):2767-70.
16 Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80.
17 Synthesis of a novel biotin-tagged photoaffinity probe for VEGF receptor tyrosine kinases. Bioorg Med Chem Lett. 2006 Jan 1;16(1):129-33.
18 Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-linea... J Med Chem. 2008 Sep 25;51(18):5680-9.
19 The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2012 Aug 1;22(15):4979-85.